Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance. Although raltegravir (RAL) and elvitegravir (EVG) resistance profiles are well-characterized, resistance patterns for dolutegravir (DTG),...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Maureen, Ibanescu, Ruxandra-Ilinca, Anstett, Kaitlin, Mésplède, Thibault, Routy, Jean-Pierre, Robbins, Marjorie A., Brenner, Bluma G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098636/
https://www.ncbi.nlm.nih.gov/pubmed/30119633
http://dx.doi.org/10.1186/s12977-018-0440-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098636/
https://www.ncbi.nlm.nih.gov/pubmed/30119633
http://dx.doi.org/10.1186/s12977-018-0440-3

Ejemplares similares